Physician Wealth Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Physician Wealth Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$756	Hold	13	–	–	﹤0.01%	1795
2025 Q4	$583	Buy	+13	New	+$546	﹤0.01%	1802

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Physician Wealth Advisors's XENE Position: Q1 2026 in Review

Physician Wealth Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q1 2026 at 13 shares worth $756. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Physician Wealth Advisors first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Physician Wealth Advisors held 13 shares of Xenon Pharmaceuticals worth $756 as of Q1 2026.
Physician Wealth Advisors left its Xenon Pharmaceuticals share count unchanged in Q1 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q1 2026, its #1795 holding.
Physician Wealth Advisors first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Physician Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.